文献速递腹部儿科影像MR

LI-RADS MRI主要及辅助征象对儿童恶性肝脏肿瘤的诊断价值

MRI major and ancillary features of LI-RADS for diagnosis of pediatric malignant liver tumors.
PubMed 文献 · Eur Radiol · 2025-06-25

该单中心回顾性研究纳入2010年1月至2023年2月因局灶性肝病变行增强MRI的儿童患者102例,由3名阅片者依据LI-RADS v2018独立分析,评估主要及辅助征象对恶性肝细胞肿瘤及整体肝脏恶性肿瘤的诊断效能,并采用多因素logistic回归识别相关征象。

要点

  • 限制性扩散对儿童恶性肝肿瘤敏感(敏感度97.9%和97.1%),但特异度中等。
  • 非周边廓清对恶性肝细胞肿瘤特异度高(94.2%),与恶性肝细胞肿瘤独立相关(校正OR 34.5)。
  • 镶嵌架构对整体肝脏恶性肿瘤特异度高(90.0%),与肝脏恶性肿瘤独立相关(校正OR 20.4)。

核心结论

  • 限制性扩散是敏感的MRI LI-RADS征象,而非周边廓清和镶嵌架构是诊断儿童恶性肝脏肿瘤的特异性征象。

研究设计与样本

  • 单中心回顾性研究,纳入2010年1月至2023年2月因局灶性肝病变行增强肝脏MRI的儿童患者102例(中位年龄4.5岁,四分位距0.6-14.0岁;男:女54:48),3名阅片者依据LI-RADS v2018独立分析,参考标准为病理诊断或随访超过1年的稳定/消退。

关键影像表现/征象

  • 非边缘动脉期强化敏感度73.4%、特异度39.6%;强化包膜敏感度56.7%、特异度92.0%;非周边廓清敏感度70.1%、特异度94.2%(诊断恶性肝细胞肿瘤)。
  • 限制性扩散诊断恶性肝细胞肿瘤敏感度97.9%、特异度53.8%;诊断整体肝脏恶性肿瘤敏感度97.1%、特异度65.8%。
  • 镶嵌架构诊断整体肝脏恶性肿瘤敏感度79.5%、特异度90.0%。

诊断标准与关键数值

  • 非周边廓清诊断恶性肝细胞肿瘤:敏感度70.1%、特异度94.2%、校正OR 34.5(p<0.001)。
  • 限制性扩散诊断恶性肝细胞肿瘤:敏感度97.9%、特异度53.8%、校正OR 72.3(p=0.001)。
  • 肿块内脂肪诊断恶性肝细胞肿瘤:敏感度29.0%、特异度93.0%、校正OR 4.3(p=0.01)。
  • 非周边廓清诊断整体肝脏恶性肿瘤:敏感度58.7%、特异度94.5%、校正OR 12.5(p<0.001)。
  • 限制性扩散诊断整体肝脏恶性肿瘤:敏感度97.1%、特异度65.8%、校正OR 31.1(p<0.001);镶嵌架构:敏感度79.5%、特异度90.0%、校正OR 20.4(p<0.001)。

临床应用与阅片要点

  • 非周边廓清、限制性扩散和镶嵌架构是诊断儿童恶性肝脏肿瘤的可靠MRI LI-RADS征象。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate LI-RADS major and ancillary features for MRI-based diagnosis of pediatric malignant liver tumors.

MATERIALS AND METHODS: This single-center retrospective study enrolled pediatric patients who underwent contrast-enhanced liver MRI for focal liver lesions from January 2010-February 2023. Three readers independently performed imaging analysis based on LI-RADS v2018. The reference standard was a pathological diagnosis or stability/regression for over one year on follow-up. Estimation of diagnostic accuracy and multivariable logistic regression were conducted to identify LI-RADS features associated with malignant hepatocellular tumors and hepatic malignancy in general.

RESULTS: Of the 102 patients (median age [interquartile range], 4.5 [0.6-14.0] years; boys:girls, 54:48), 58.8% (60/102) had malignant liver tumors and 49.0% (50/102) had malignant hepatocellular tumors. The sensitivity and specificity of major features for diagnosis of malignant hepatocellular tumors were as follows: nonrim arterial enhancement, 73.4% and 39.6%; enhancing capsule, 56.7% and 92.0%; nonperipheral washout, 70.1% and 94.2%. Nonperipheral washout (sensitivity, 70.1%; specificity, 94.2%; adjusted OR, 34.5; p < 0.001), restricted diffusion (sensitivity, 97.9%; specificity, 53.8%; adjusted OR, 72.3; p = 0.001), and fat-in-mass (sensitivity, 29.0%; specificity, 93.0%; adjusted OR, 4.3; p = 0.01) were associated with malignant hepatocellular tumors, while nonperipheral washout (sensitivity, 58.7%; specificity, 94.5%; adjusted OR, 12.5; p < 0.001), restricted diffusion (sensitivity, 97.1%; specificity, 65.8%; adjusted OR, 31.1; p < 0.001), and mosaic architecture (sensitivity, 79.5%; specificity, 90.0%; adjusted OR, 20.4; p < 0.001) were associated with hepatic malignancy in general.

CONCLUSION: Restricted diffusion was a sensitive MRI LI-RADS feature, while nonperipheral washout and mosaic architecture were specific features for diagnosing pediatric malignant liver tumors.

KEY POINTS: Questions MRI is the recommended modality for pediatric focal liver lesions, but only a few studies have examined the diagnostic accuracy of MRI LI-RADS features in children. Findings Restricted diffusion was sensitive for malignant liver tumors, while mosaic architectures were specific for malignant liver tumors. Nonperipheral washout was specific for diagnosing malignant hepatocellular tumors. Clinical relevance Nonperipheral washout, restricted diffusion, and mosaic architecture were reliable MRI LI-RADS features for diagnosing pediatric malignant liver tumors.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Choi SJ, Shin JI, Kim PH, et al. MRI major and ancillary features of LI-RADS for diagnosis of pediatric malignant liver tumors. Eur Radiol. 2025. PMID: 40560413. doi:10.1007/s00330-025-11775-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。